ArticleCureus2025
Interaction Between HAQ-STING Mutation and COPA: Protection Against COPA Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOPA syndrome is a rare autoinflammatory disorder caused by mutations in the COPA gene, leading to immune dysregulation and inflammatory pathology. The HAQ variant of stimulator of interferon genes (STING) allele has been identified as a protective factor against disease manifestation. Understanding the molecular interaction between HAQ-STING and COPA is critical for uncovering potential therapeutic strategies.
methodsThis study utilized AlphaFold2 Multimer (AF2M) (DeepMind, London, UK) an extension of AlphaFold2 designed to predict the structures of protein complexes (multimers), to analyze the structural interaction between COPA, STING, and HAQ-STING. PyMOL (Schrödinger, Inc., New York, USA) was used for molecular visualization and analysis of conformational differences in protein-protein interactions (PPIs). Structural alignment and binding pocket analysis were conducted to assess the potential impact of HAQ-STING on COPA function. Molecular docking studies were conducted with AutoDock Vina Extended (OneAngstrom, Grenoble, France).
resultsAF2M analysis revealed that HAQ-STING causes a 90-degree rotational shift in its binding orientation to COPA compared to STING, inducing significant conformational rearrangements. The interaction alters COPA's structural stability, suggesting an allosteric regulatory mechanism. A potential binding channel for a small therapeutic molecule was identified at the interface of STING and COPA. If the channel in the COPA STING interface meets criteria for depth, stability, and functional significance, it could be a drug-binding pocket. A therapeutic small molecule docked in a binding pocket at the interface of two interacting proteins can disrupt the protein-protein complex. This approach, known as PPI inhibition, is a well-established strategy in drug discovery. Fosfomycin, a phosphate-containing molecule, docked in the channel at the interface of COPA and STING.
conclusionThis study provides novel structural insights into the protective role of HAQ-STING in COPA syndrome. The conformational shift induced by HAQ-STING may modulate immune signaling, preventing disease manifestation. A potential binding channel for a small therapeutic molecule was identified at the interface of STING and COPA; fosfomycin was docked in this channel. These findings highlight potential therapeutic avenues, including gene therapy, small-molecule inhibitors, and STING pathway modulation. Further experimental validation is needed to translate these structural insights into clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.